Compare · RVTY vs TLIS
RVTY vs TLIS
Side-by-side comparison of Revvity Inc. (RVTY) and Talis Biomedical Corporation (TLIS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TLIS operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 119.0x TLIS ($145.1M).
- RVTY has hit the wire 5 times in the past 4 weeks while TLIS has been quiet.
- RVTY has more recent analyst coverage (23 ratings vs 5 for TLIS).
- Company
- Revvity Inc.
- Talis Biomedical Corporation
- Price
- $152.62-1.34%
- $4.41+6.78%
- Market cap
- $17.26B
- $145.1M
- 1M return
- +4.01%
- -
- 1Y return
- +60.03%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 23
- 5
Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Latest TLIS
- Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation
- SEC Form 15-12G filed by Talis Biomedical Corporation
- SEC Form 25-NSE filed by Talis Biomedical Corporation
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits